WP5: Translational Application for the Characterization and ex vivo Expansion of Human Erythroid Progenitor Cells

Actions

Order Studies

Overview
Related items

No description specified

SEEK ID: https://fairdomhub.org/investigations/106

Projects: SBEpo - Systems Biology of Erythropoietin

Investigation position:

Help

Tree Split Graph

Export PNG

Click below to download a copy of the image

Download

Creators and Submitter

Creators

Lorenz Adlung
Andreas Franke
Rainer Saffrich
Marie-Christine Wagner
Marcel Schilling

Submitter

Maja Rey

Activity

Views: 3027

Created: 11th Oct 2016 at 09:28

Related items

People (6)
Programmes (1)
Projects (1)
Studies (0+3)
Publications (9)

Advanced People list for this Investigation with search and filtering

Lorenz Adlung

Projects: SBEpo - Systems Biology of Erythropoietin

Institutions: German Cancer Research Center (DKFZ)

https://orcid.org/0000-0002-0971-2309

Expertise: Mathematical modelling, Single Cell analysis, Cell biology, Molecular Biology

Tools: Biochemistry, Systems Biology, Matlab, R

Andreas Franke

Projects: SBEpo - Systems Biology of Erythropoietin

Institutions: Roche Diagnostics

Maja Rey

Projects: SysMO-LAB, de.NBI-SysBio, Kinetics on the move - Workshop 2016, Example use cases, SBEpo - Systems Biology of Erythropoietin, FAIRDOM & LiSyM & de.NBI Data Structuring Training, FAIRDOM, EnzymeML, FAIRDOM Community Workers, GMDS Project Group "FAIRe Dateninfrastrukturen für die Biomedizinische Informatik", MIX-UP, COVID-19 Disease Map, ERNEST Mapping Group Pilot Study, CC-TOP, SABIO-VIS, SDBV/HITS

Institutions: Heidelberg Institute for Theoretical Studies

Expertise: Biochemistry, Molecular Biology, Microbiology, Phytopathology, Data curation

Tools: SABIO-RK, SEEK

Within the de.NBI project my functions in the de.NBI-SysBio node comprise content curation, requirements elicitation, and community engagement for the users of biochemical reaction kinetics database SABIO-RK as well as of the data management platform SEEK.

Rainer Saffrich

Projects: SBEpo - Systems Biology of Erythropoietin

Institutions: University Hospital Heidelberg

Marcel Schilling

Projects: SBEpo - Systems Biology of Erythropoietin, MS_DILI

Institutions: German Cancer Research Center (DKFZ)

https://orcid.org/0000-0002-9517-5166

Expertise: Systems Biology, Cell biology, Cell Cycle, Mathematical modelling, Cancer research, signal transduction, MAP-kinase

Marie-Christine Wagner

Projects: SBEpo - Systems Biology of Erythropoietin

Institutions: German Cancer Research Center (DKFZ)

Advanced Programmes list for this Investigation with search and filtering

e:Bio

e:Bio - Innovations Competition Systems Biology

Projects: SulfoSys - Biotec, SBEpo - Systems Biology of Erythropoietin

Web page: http://www.fona.de/en/14276

Advanced Projects list for this Investigation with search and filtering

SBEpo - Systems Biology of Erythropoietin

Multi-level mathematical modeling of erythropoiesis for optimized expansion of erythroid progenitor cells and improved treatment regimes

Programme: e:Bio

Public web page: Not specified

Organisms: Homo sapiens, Mus musculus

Advanced Studies list for this Investigation with search and filtering

3 hidden items

Advanced Publications list for this Investigation with search and filtering

Protein abundance of AKT and ERK pathway components governs cell type-specific regulation of proliferation.

SBEpo - Systems Biology of Erythropoietin

(Show All)

All authors

Lorenz Adlung

Marie-Christine Wagner

Sajib Chakraborty

Hauke Busch

Marcel Schilling

Abstract (Expand)

Signaling through the AKT and ERK pathways controls cell proliferation. However, the integrated regulation of this multistep process, involving signal processing, cell growth and cell cycle progression, … is poorly understood. Here, we study different hematopoietic cell types, in which AKT and ERK signaling is triggered by erythropoietin (Epo). Although these cell types share the molecular network topology for pro-proliferative Epo signaling, they exhibit distinct proliferative responses. Iterating quantitative experiments and mathematical modeling, we identify two molecular sources for cell type-specific proliferation. First, cell type-specific protein abundance patterns cause differential signal flow along the AKT and ERK pathways. Second, downstream regulators of both pathways have differential effects on proliferation, suggesting that protein synthesis is rate-limiting for faster cycling cells while slower cell cycles are controlled at the G1-S progression. The integrated mathematical model of Epo-driven proliferation explains cell type-specific effects of targeted AKT and ERK inhibitors and faithfully predicts, based on the protein abundance, anti-proliferative effects of inhibitors in primary human erythroid progenitor cells. Our findings suggest that the effectiveness of targeted cancer therapy might become predictable from protein abundance.

Authors: L. Adlung, S. Kar, M. C. Wagner, B. She, S. Chakraborty, J. Bao, S. Lattermann, M. Boerries, H. Busch, P. Wuchter, A. D. Ho, J. Timmer, M. Schilling, T. Hofer, U. Klingmuller

Date Published: 24th Jan 2017

Publication Type: Journal Article

PubMed ID: 28123004

Citation: Mol Syst Biol. 2017 Jan 24;13(1):904. doi: 10.15252/msb.20167258.

Created: 31st Jan 2017 at 13:05, Last updated: 8th Dec 2022 at 17:26

Evaluation of GMP-compliant culture media for in vitro expansion of human bone marrow mesenchymal stromal cells.

SBEpo - Systems Biology of Erythropoietin

All authors

Rainer Saffrich

Abstract (Expand)

Mesenchymal stromal cells (MSCs) from human bone marrow serve as a resource for cell-based therapies in regenerative medicine. Clinical applications require standardized protocols according to good … manufacturing practice (GMP) guidelines. Donor variability as well as the intrinsic heterogeneity of MSC populations must be taken into consideration. The composition of the culture medium is a key factor in successful MSC expansion. The aim of this study was to comparatively assess the efficiency of xeno-free human platelet lysate (HPL)-based cell expansion with two commercially available media-StemPro MSC SFM CTS (for human ex vivo tissue and cell culture processing applications) and MSCGM (non-GMP-compliant, for research only)-in an academic setting as the first optimization step toward GMP-compliant manufacturing. We report the feasibility of MSC expansion up to the yielded cell number with all three media. MSCs exhibited the typical fibroblastoid morphology, with distinct differences in cell size depending on the medium. The differentiation capacity and characteristic immunophenotype were confirmed for all MSC populations. Proliferation was highest using StemPro MSC SFM CTS, whereas HPL medium was more cost-effective and its composition could be adjusted individually according to the respective needs. In summary, we present a comprehensive evaluation of GMP-compatible culture media for MSC expansion. Both StemPro and HPL medium proved to be suitable for clinical application and allowed sufficient cell proliferation. Specific differences were observed and should be considered according to the intended use. This study provides a detailed cost analysis and tools that may be helpful for the establishment of GMP-compliant MSC expansion.

Authors: P. Wuchter, M. Vetter, R. Saffrich, A. Diehlmann, K. Bieback, A. D. Ho, P. Horn

Date Published: 26th Feb 2016

Publication Type: Journal Article

PubMed ID: 26911671

Citation: Exp Hematol. 2016 Jun;44(6):508-18. doi: 10.1016/j.exphem.2016.02.004. Epub 2016 Feb 19.

Created: 13th Oct 2016 at 09:56, Last updated: 8th Dec 2022 at 17:26

Microcavity arrays as an in vitro model system of the bone marrow niche for hematopoietic stem cells.

SBEpo - Systems Biology of Erythropoietin

All authors

Rainer Saffrich

Abstract (Expand)

In previous studies human mesenchymal stromal cells (MSCs) maintained the "stemness" of human hematopoietic progenitor cells (HPCs) through direct cell-cell contact in two-dimensional co-culture … systems. We establish a three-dimensional (3D) co-culture system based on a custom-made chip, the 3(D)-KITChip, as an in vitro model system of the human hematopoietic stem cell niche. This array of up to 625 microcavities, with 300 mum size in each orientation, was inserted into a microfluidic bioreactor. The microcavities of the 3(D)-KITChip were inoculated with human bone marrow MSCs together with umbilical cord blood HPCs. MSCs used the microcavities as a scaffold to build a complex 3D mesh. HPCs were distributed three-dimensionally inside this MSC network and formed ss-catenin- and N-cadherin-based intercellular junctions to the surrounding MSCs. Using RT(2)-PCR and western blots, we demonstrate that a proportion of HPCs maintained the expression of CD34 throughout a culture period of 14 days. In colony-forming unit assays, the hematopoietic stem cell plasticity remained similar after 14 days of bioreactor co-culture, whereas monolayer co-cultures showed increasing signs of HPC differentiation and loss of stemness. These data support the notion that the 3D microenvironment created within the microcavity array preserves vital stem cell functions of HPCs more efficiently than conventional co-culture systems.

Authors: P. Wuchter, R. Saffrich, S. Giselbrecht, C. Nies, H. Lorig, S. Kolb, A. D. Ho, E. Gottwald

Date Published: 3rd Feb 2016

Publication Type: Journal Article

PubMed ID: 26829941

Citation: Cell Tissue Res. 2016 Jun;364(3):573-584. doi: 10.1007/s00441-015-2348-8. Epub 2016 Jan 30.

Created: 13th Oct 2016 at 10:02, Last updated: 8th Dec 2022 at 17:26

Mesenchymal stromal cells inhibit proliferation of virus-specific CD8(+) T cells.

SBEpo - Systems Biology of Erythropoietin

Abstract (Expand)

Mesenchymal stromal cells (MSCs) possess broad immunomodulatory capacities that are currently investigated for potential clinical application in treating autoimmune disorders. Third-party MSCs suppress … alloantigen-induced proliferation of peripheral blood mononuclear cells providing the rationale for clinical use in graft-versus-host disease (GvHD). We confirmed that MSCs strongly inhibited proliferation of CD8(+) T cells in a mixed lymphocyte reaction. However, MSCs also suppressed proliferation of T cells specifically recognizing cytomegalovirus (CMV) and influenza virus. Inhibition was dose dependent, but independent of the culture medium. MSCs inhibited proliferation of specific CD8(+) T cells and the release of IFN-gamma by specific CD8(+) T cells for immunodominant HLA-A2- and HLA-B7- restricted antigen epitopes derived from CMV phosphoprotein 65 and influenza matrix protein. This is in contrast to a recently reported scenario where MSCs exert differential effects on alloantigen and virus-specific T cells potentially having an impact on surveillance and prophylaxis of patients treated by MSCs.

Authors: G. Malcherek, N. Jin, A. G. Huckelhoven, J. Mani, L. Wang, U. Gern, A. Diehlmann, P. Wuchter, A. Schmitt, B. Chen, A. D. Ho, M. Schmitt

Date Published: 18th Sep 2014

Publication Type: Journal Article

PubMed ID: 25227910

Citation: Leukemia. 2014 Dec;28(12):2388-94. doi: 10.1038/leu.2014.273. Epub 2014 Sep 17.

Created: 13th Oct 2016 at 10:11, Last updated: 8th Dec 2022 at 17:26

Standardization of Good Manufacturing Practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications.

SBEpo - Systems Biology of Erythropoietin

All authors

Rainer Saffrich

Abstract (Expand)

BACKGROUND AIMS: Human mesenchymal stem or stromal cells (MSCs) represent a potential resource not only for regenerative medicine but also for immunomodulatory cell therapies. The application of different … MSC culture protocols has significantly hampered the comparability of experimental and clinical data from different laboratories and has posed a major obstacle for multicenter clinical trials. Manufacturing of cell products for clinical application in the European Community must be conducted in compliance with Good Manufacturing Practice and requires a manufacturing license. In Germany, the Paul-Ehrlich-Institut as the Federal Authority for Vaccines and Biomedicines is critically involved in the approval process. METHODS: This report summarizes a consensus meeting between researchers, clinicians and regulatory experts on standard quality requirements for MSC production. RESULTS: The strategy for quality control testing depends on the product's cell composition, the manufacturing process and the indication and target patient population. Important quality criteria in this sense are, among others, the immunophenotype of the cells, composition of the culture medium and the risk for malignant transformation, as well as aging and the immunosuppressive potential of the manufactured MSCs. CONCLUSIONS: This position paper intends to provide relevant information to interested parties regarding these criteria to foster the development of scientifically valid and harmonized quality standards and to support approval of MSC-based investigational medicinal products.

Authors: P. Wuchter, K. Bieback, H. Schrezenmeier, M. Bornhauser, L. P. Muller, H. Bonig, W. Wagner, R. Meisel, P. Pavel, T. Tonn, P. Lang, I. Muller, M. Renner, G. Malcherek, R. Saffrich, E. C. Buss, P. Horn, M. Rojewski, A. Schmitt, A. D. Ho, R. Sanzenbacher, M. Schmitt

Date Published: 27th May 2014

Publication Type: Journal Article

PubMed ID: 24856898

Citation: Cytotherapy. 2015 Feb;17(2):128-39. doi: 10.1016/j.jcyt.2014.04.002. Epub 2014 May 20.

Created: 13th Oct 2016 at 10:13, Last updated: 8th Dec 2022 at 17:26

Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells.

SBEpo - Systems Biology of Erythropoietin

All authors

Rainer Saffrich

Abstract (Expand)

The interaction between the stromal cell-derived factor-1 alpha (SDF-1alpha, CXCL12) and its chemokine receptor CXCR4 has been reported to regulate stem cell migration, mobilization and homing. The … CXCR4 antagonist plerixafor is highly efficient in mobilizing hematopoietic progenitor cells (HPCs). However, the precise regulatory mechanisms governing the CXCR4/SDF-1alpha axis between the bone marrow niche and HPCs remain unclear. In this study, we quantify the impact of plerixafor on the interaction between human bone marrow derived mesenchymal stromal cells (MSCs) and human CD34+ HPCs. An assessment of SDF-1alpha levels in the supernatant of MSC cultures revealed that exposure to plerixafor led to a transient increase but had no long-term effect. In Transwell experiments, we observed that the addition of SDF-1alpha significantly stimulated HPC migration; this stimulation was almost completely antagonized by the addition of plerixafor, confirming the direct impact of the CXCR4/SDF-1alpha interaction on the migration capacity of HPCs. We also developed a new microstructural niche model to determine the chemotactic sensitivity of HPCs. Time-lapse microscopy demonstrated that HPCs migrated actively along an SDF-1alpha gradient within the microchannels and the quantitative assessment of the required minimum gradient initiating this chemotaxis revealed a surprisingly high sensitivity of HPCs. These data demonstrate the fine-tuned balance of the CXCR4/SDF-1alpha axis and the synergistic effects of plerixafor on HPCs and MSCs, which most likely represent the key mechanisms for the consecutive mobilization of HPCs from the bone marrow niche into the circulating blood.

Authors: P. Wuchter, C. Leinweber, R. Saffrich, M. Hanke, V. Eckstein, A. D. Ho, M. Grunze, A. Rosenhahn

Date Published: 17th Dec 2013

Publication Type: Journal Article

PubMed ID: 24337688

Citation: Cell Tissue Res. 2014 Feb;355(2):315-26. doi: 10.1007/s00441-013-1759-7. Epub 2013 Dec 14.

Created: 13th Oct 2016 at 10:17, Last updated: 8th Dec 2022 at 17:26

Differences between healthy hematopoietic progenitors and leukemia cells with respect to CD44 mediated rolling versus adherence behavior on hyaluronic acid coated surfaces.

SBEpo - Systems Biology of Erythropoietin

Abstract (Expand)

We previously demonstrated that leukemia cell lines expressing CD44 and hematopoietic progenitor cells (HPC) from umbilical cord blood (CB) showed rolling on hyaluronic acid (HA)-coated surfaces under … physiological shear stress. In the present study, we quantitatively assessed the interaction of HPC derived from CB, mobilized peripheral blood (mPB) and bone marrow (BM) from healthy donors, as well as primary leukemia blasts from PB and BM of patients with acute myeloid leukemia (AML) with HA. We have demonstrated that HPC derived from healthy donors showed relative homogeneous rolling and adhesion to HA. In contrast, highly diverse behavioral patterns were found for leukemia blasts under identical conditions. The monoclonal CD44 antibody (clone BU52) abrogated the shear stress-induced rolling of HPC and leukemia blasts, confirming the significance of CD44 in this context. On the other hand, the immobile adhesion of leukemia blasts to the HA-coated surface was, in some cases, not or incompletely inhibited by BU52. The latter property was associated with non-responsiveness to induction chemotherapy and subsequently poor clinical outcome.

Authors: M. Hanke, I. Hoffmann, C. Christophis, M. Schubert, V. T. Hoang, A. Zepeda-Moreno, N. Baran, V. Eckstein, P. Wuchter, A. Rosenhahn, A. D. Ho

Date Published: 26th Nov 2013

Publication Type: Journal Article

PubMed ID: 24269154

Citation: Biomaterials. 2014 Feb;35(5):1411-9. doi: 10.1016/j.biomaterials.2013.11.011. Epub 2013 Nov 22.

Created: 13th Oct 2016 at 10:19, Last updated: 8th Dec 2022 at 17:26

Functional potentials of human hematopoietic progenitor cells are maintained by mesenchymal stromal cells and not impaired by plerixafor.

SBEpo - Systems Biology of Erythropoietin

All authors

Rainer Saffrich

Abstract (Expand)

BACKGROUND AIMS: Mesenchymal stromal cells (MSCs) resemble an essential component of the bone marrow niche for maintenance of stemness of hematopoietic progenitor cells (HPCs). Perturbation of the C-X-C … chemokine receptor type 4 (CXCR4)/stromal cell-derived factor-1alpha (SDF-1alpha) axis by plerixafor (AMD3100) mobilizes HPCs from their niche; however, little is known about how plerixafor affects interaction of HPCs and MSCs in vitro. METHODS: We monitored cell division kinetics, surface expression of CD34 and CXCR4, migration behavior and colony-forming frequency of HPCs on co-culture with MSCs either with or without exposure to plerixafor. RESULTS: Co-culture with MSCs significantly accelerated cell division kinetics of HPCs. Despite this, the proportion of CD34(+) cells was significantly increased on co-culture, whereas the expression of CXCR4 was reduced. In addition, co-culture with MSCs led to significantly higher colony-forming capacity and enhanced migration rate of HPCs compared with mono-culture conditions. The composition of MSC sub-populations-and conversely their hematopoiesis supportive functions-may be influenced by culture conditions. We compared the stromal function of MSCs isolated with three different culture media. Overall, the supporting potentials of these MSC preparations were quite similar. Perturbation by the CXCR4-antagonist plerixafor reduced the cell division kinetics of HPCs on co-culture with MSCs. However, the progenitor cell potential of the HPCs as reflected by colony-forming capacity was not affected by plerixafor. CONCLUSIONS: These results support the notion that the CXCR4/SDF-1alpha axis is critical for HPC-MSC interaction with regard to migration, adhesion and regulation of proliferation but not for maintenance of primitive progenitor cells.

Authors: A. Ludwig, R. Saffrich, V. Eckstein, T. Bruckner, W. Wagner, A. D. Ho, P. Wuchter

Date Published: 15th Oct 2013

Publication Type: Journal Article

PubMed ID: 24119647

Citation: Cytotherapy. 2014 Jan;16(1):111-21. doi: 10.1016/j.jcyt.2013.07.007. Epub 2013 Oct 10.

Created: 13th Oct 2016 at 11:21, Last updated: 8th Dec 2022 at 17:26

[Mesenchymal stroma cells (MSCs) for the treatment of rheumatic disease].

SBEpo - Systems Biology of Erythropoietin

Abstract

Not specified

Authors: M. Schmitt, L. P. Muller, G. Keysser, H. M. Lorenz, A. D. Ho, P. Wuchter

Date Published: 6th Sep 2013

Publication Type: Journal Article

PubMed ID: 24006170

Citation: Dtsch Med Wochenschr. 2013 Sep;138(37):1852-5. doi: 10.1055/s-0033-1343346. Epub 2013 Sep 4.

Created: 13th Oct 2016 at 11:22, Last updated: 8th Dec 2022 at 17:26